Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-483-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$51.49 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.01. The biopharmaceutical company earned $24.15 million during the quarter, compared to analyst estimates of $22.16 million. Ultragenyx Pharmaceutical had a negative return on equity of 49.84% and a negative net margin of 527.49%. Ultragenyx Pharmaceutical's revenue was up 88.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.06) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
13 brokerages have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their predictions range from $59.00 to $94.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $76.1538 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)
- 2. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults, with X-linked hypophosphatemia (XLH) in the United States. The company looks forward to expand the global commercial reach of its approved therapies in 2019. It also expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders in the year. Ultragenyx continues to advance the two gene therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency — with additional data expected to be released in 2019. However, Since Ultragenyx is a newly commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have widened ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2019)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
News coverage about RARE stock has been trending negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Ultragenyx Pharmaceutical.
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Mylan (MYL), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC) and Teva Pharmaceutical Industries (TEVA).
What other stocks do shareholders of Ultragenyx Pharmaceutical own?
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Emil D. Kakkis, President, Chief Executive Officer & Director
- Wladimir Hogenhuis, Chief Operating Officer
- Shalini Sharp, Chief Financial Officer & Executive Vice President
- Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
- Eric Crombez, Chief Medical Officer
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.68%), Price T Rowe Associates Inc. MD (7.99%), BlackRock Inc. (7.65%), First Trust Advisors LP (2.64%), Northern Trust Corp (1.20%) and Highline Capital Management L.P. (0.68%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which major investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, BlackRock Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., Highline Capital Management L.P., SG Americas Securities LLC, Capital International Sarl and Asset Management One Co. Ltd.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which major investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, First Light Asset Management LLC, Vanguard Group Inc., DekaBank Deutsche Girozentrale, Orbimed Advisors LLC, Morgan Stanley and Rothschild & Co. Asset Management US Inc.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $58.65.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $3.38 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.
What is Ultragenyx Pharmaceutical's official website?
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
